These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 6578210)

  • 1. Pharmacokinetics of N-formimidoyl thienamycin and influence of a renal dipeptidase inhibitor in experimental meningitis.
    Washburn DE; Perfect JR; Durack DT
    J Antimicrob Chemother; 1983 Jul; 12(1):39-45. PubMed ID: 6578210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrathecal penetration of N-formimidoyl thienamycin in normal rabbits: potentiation by coadministration of renal dipeptidase enzyme inhibitor.
    Chow AW; Finlay KR; Stiver HG; Carlson CL
    Antimicrob Agents Chemother; 1983 Apr; 23(4):634-6. PubMed ID: 6574725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors.
    Norrby SR; Alestig K; Björnegård B; Burman LA; Ferber F; Huber JL; Jones KH; Kahan FM; Kahan JS; Kropp H; Meisinger MA; Sundelof JG
    Antimicrob Agents Chemother; 1983 Feb; 23(2):300-7. PubMed ID: 6573157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans.
    Norrby SR; Alestig K; Ferber F; Huber JL; Jones KH; Kahan FM; Meisinger MA; Rogers JD
    Antimicrob Agents Chemother; 1983 Feb; 23(2):293-9. PubMed ID: 6573156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and bacteriological efficacy of N-formimidoyl thienamycin in experimental Escherichia coli meningitis.
    Patamasucon P; McCracken GH
    Antimicrob Agents Chemother; 1982 Mar; 21(3):390-2. PubMed ID: 7049073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [N-Formimidoyl-thienamycin in Animal Studies].
    Ritzerfeld W
    Arzneimittelforschung; 1983; 33(3):470-2. PubMed ID: 6575782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocular penetration of N-formimidoyl thienamycin (MK-787) and potentiation by dipeptidase inhibitor (MK-791).
    Finlay KR; Carlson CL; Chow AW
    Invest Ophthalmol Vis Sci; 1983 Aug; 24(8):1147-9. PubMed ID: 6575970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. beta-Lactamase activity of renal dipeptidase against N-formimidoyl-thienamycin.
    Kim HS; Campbell BJ
    Biochem Biophys Res Commun; 1982 Oct; 108(4):1638-42. PubMed ID: 6983880
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of staphylococcal pyelonephritis in rats with N-formimidoyl thienamycin.
    Guze PA; Kalmanson GM; Ishida K; Freedman LR; Guze LB
    Chemioterapia; 1984 Feb; 3(1):53-6. PubMed ID: 6598578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thienamycin: development of imipenen-cilastatin.
    Kahan FM; Kropp H; Sundelof JG; Birnbaum J
    J Antimicrob Chemother; 1983 Dec; 12 Suppl D():1-35. PubMed ID: 6365872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Penetration of N-formimidoyl thienamycin into extravascular fluids in rabbits.
    Olay T; Vicente MV; Rodríguez A
    Chemotherapy; 1986; 32(5):404-7. PubMed ID: 3463447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase.
    Kropp H; Sundelof JG; Hajdu R; Kahan FM
    Antimicrob Agents Chemother; 1982 Jul; 22(1):62-70. PubMed ID: 7125632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized study comparing clinical efficacy and safety of thienamycin formamidine (MK0787)/renal dipeptidase inhibitor (MK0791) and cefazolin.
    Ribner BS; Raeder R; Hollstein M; Freimer EH
    J Antimicrob Chemother; 1983 Oct; 12(4):387-91. PubMed ID: 6358177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure.
    Verpooten GA; Verbist L; Buntinx AP; Entwistle LA; Jones KH; De Broe ME
    Br J Clin Pharmacol; 1984 Aug; 18(2):183-93. PubMed ID: 6593092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative stability of newly introduced beta-lactam antibiotics to renal dipeptidase.
    Mikami H; Ogashiwa M; Saino Y; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1982 Oct; 22(4):693-5. PubMed ID: 7181478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of in vivo and in vitro bactericidal activity of N-formimidoyl thienamycin against enterococci.
    Auckenthaler R; Wilson WR; Wright AJ; Washington JA; Durack DT; Geraci JE
    Antimicrob Agents Chemother; 1982 Sep; 22(3):448-52. PubMed ID: 6958215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro and in-vivo antibacterial activity of imipenem against clinical isolates of bacteria.
    Mitsuhashi S
    J Antimicrob Chemother; 1983 Dec; 12 Suppl D():53-64. PubMed ID: 6607914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The morphological response of Pseudomonas aeruginosa to azthreonam, cefoperazone, ceftazidime and N-formimidoyl thienamycin.
    Elliott TS; Greenwood D
    J Med Microbiol; 1984 Apr; 17(2):159-69. PubMed ID: 6423826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative stability of first, second and third generation cephalosporins and N-formimidoyl thienamycin against gram-negative beta-lactamases.
    Vuye A
    Arzneimittelforschung; 1983; 33(9):1236-9. PubMed ID: 6605753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Affinity of N-formimidoyl-thienamycin (MK-0787) for beta-lactamases, analysis by a statistical method: correspondence analysis].
    Labia R; Guionie M; Morand A; Barthélémy M; Doré JC
    Ann Microbiol (Paris); 1983; 134A(1):29-38. PubMed ID: 6601926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.